Drug interactions
Empagliflozin-linagliptin + Encorafenib
Severity: Moderate
Empagliflozin-linagliptin and Encorafenib: moderate interaction.
Last updated
For healthcare professionals — reference only. This page is a brief summary, not medical advice and not a substitute for official labeling or clinical judgement. Always verify before prescribing or dispensing.
Summary
Encorafenib both inhibits and induces CYP3A4, so linagliptin exposure could rise or fall. The net clinical effect is uncertain, and linagliptin is only partly metabolized by CYP3A4. Encorafenib can also raise blood glucose.
What this interaction means in plain words
Empagliflozin-linagliptin and Encorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken.
Empagliflozin-linagliptin belongs to Endocrine; Encorafenib belongs to Oncology.
Why it happens
Mixed CYP3A4 inhibition and induction by encorafenib may alter linagliptin metabolism.
What to do
Monitor blood glucose regularly during encorafenib therapy and adjust the antidiabetic regimen if glycemic control changes.
What to ask your pharmacist
- Should I take them at different times of day?
- Does the dose of either medicine need to change?
- Is there anything I should avoid, such as alcohol or certain foods, while on both?
Pro+ members
Unlock the full page
Create an account and start a Pro+ trial to unlock the full management advice for Empagliflozin-linagliptin and Encorafenib, the additional notes, the evidence detail and the whole-prescription interaction checker.
- Full clinical management advice
- Additional notes
- Evidence detail
- Interaction checker for a whole prescription
Try Pro+ free for 7 days on the web. No card needed.
Other interactions of Empagliflozin-linagliptin
Other interactions of Encorafenib
Frequently asked questions
Can I take Empagliflozin-linagliptin with Encorafenib?
MediHelp rates the interaction as moderate. Empagliflozin-linagliptin and Encorafenib can affect each other. The combination is often manageable, but it may need a change of dose, a change of timing, or extra checks while both are taken. Encorafenib both inhibits and induces CYP3A4, so linagliptin exposure could rise or fall. The net clinical effect is uncertain, and linagliptin is only partly metabolized by CYP3A4. Encorafenib can also raise blood glucose.
How serious is the interaction between Empagliflozin-linagliptin and Encorafenib?
MediHelp rates it moderate, on a four-level scale (minor, moderate, major, contraindicated) based on published labels and references. What to do, in brief: Monitor blood glucose regularly during encorafenib therapy and adjust the antidiabetic regimen if glycemic control changes.
What other medicines interact with Empagliflozin-linagliptin?
MediHelp also lists interactions of Empagliflozin-linagliptin with, for example, Fosphenytoin, Rifampin, Rifapentine. The full list is on the Empagliflozin-linagliptin page.
Full monographs, dosing and an interaction checker in the MediHelp app
Open the complete reference, check multi-drug interactions and use dosing tools in the MediHelp app.
